亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort

STK11段 免疫疗法 克拉斯 队列 医学 癌症 肿瘤科 突变 癌症免疫疗法 内科学 生物 遗传学 基因 结直肠癌
作者
Andrea Olsen,Alexandra Lebedeva,Polina Nosova,V. Nikulin,Margarita Sharova,E. Ignatova,Vladislav Mileyko,Maxim Ivanov
出处
期刊:Tumori Journal [SAGE Publishing]
卷期号:110 (2): 146-152 被引量:2
标识
DOI:10.1177/03008916231204441
摘要

Introduction: Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort. Methods: We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular profiling data from patients receiving immune checkpoint inhibitors). In both studies, high throughput sequencing was used for molecular profiling. Results: A total of 10,336 patients receiving antitumor therapy (MSK-IMPACT study) and 1661 patients receiving immune checkpoint inhibitors (MSK-TMB study) were included in the analysis. Co-mutation STK11/KRAS was found in 156 (1.5%) and 46 (2.8%) patients in the two studies, respectively. Most patients with the STK11/KRAS co-mutation had non-small cell lung cancer (83% and 85% in the two studies, respectively). Among non-small cell lung cancer patients, the STK11 mutation was associated with a worse outcome for patients receiving systemic antitumor therapy, but not immune checkpoint inhibition therapy (HR for OS 1.90 [95% CI 1.36-2.65] and 1.44 [95% CI 0.88-2.37]). Co-mutation STK11/KRAS was also not associated with patient outcome in any of the studies (HR for OS 0.93 [95% CI 0.56-1.52] and 1.09 [95% CI 0.54-2.19]). High tumor mutational burden was associated with better outcome in the cohort of patients receiving immune checkpoint inhibitors. An analogous analysis among patients in the pan-cancer cohort (excluding patients with non-small cell lung cancer) showed STK11 mutations and high tumor mutational burden have a predictive role for the efficacy of immune checkpoint inhibitors, but not STK11/KRAS co-mutation. Conclusions: Co-mutation STK11/KRAS is common among patients with non-small cell lung cancer and is not an independent predictive marker for the efficacy of immune checkpoint inhibitors. Further studies are required to clarify the role of STK11 mutations in immune checkpoint inhibitor treatment response.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
34秒前
顺心蜜粉发布了新的文献求助200
38秒前
葛力完成签到,获得积分20
39秒前
40秒前
量子星尘发布了新的文献求助10
50秒前
53秒前
916应助葛力采纳,获得10
55秒前
59秒前
1分钟前
朴素的山蝶完成签到 ,获得积分10
1分钟前
1分钟前
夜洛乌泽发布了新的文献求助10
1分钟前
1分钟前
顺心蜜粉发布了新的文献求助10
1分钟前
1分钟前
1分钟前
背后梦安发布了新的文献求助30
1分钟前
1分钟前
善学以致用应助lf采纳,获得10
2分钟前
2分钟前
2分钟前
lf发布了新的文献求助10
2分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
2分钟前
linkman完成签到,获得积分10
2分钟前
linkman发布了新的文献求助10
2分钟前
3分钟前
旅途规律完成签到,获得积分10
3分钟前
3分钟前
3分钟前
CodeCraft应助科研通管家采纳,获得10
3分钟前
充电宝应助科研通管家采纳,获得10
3分钟前
4分钟前
苹果果汁发布了新的文献求助30
4分钟前
charih完成签到 ,获得积分10
4分钟前
4分钟前
苹果果汁完成签到,获得积分10
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520749
关于积分的说明 11204693
捐赠科研通 3257497
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629